Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Photosensitivity in Cutaneous Lupus Erythematosus
NCT05048238Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tofacitinib oral solution in cutaneous lupus erythematosus (CLE), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Change in Percentage of UVB-induced Apoptotic Epidermal Cells at Day 26. Started Sep 2022; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05048238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048238.